AI assistant
MANNKIND CORP — Director's Dealing 2025
May 16, 2025
31835_dirs_2025-05-15_f5f72d3a-1bb3-4fdb-83b9-405593c227aa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MANNKIND CORP (MNKD)
CIK: 0000899460
Period of Report: 2025-05-13
Reporting Person: Singh Sanjay R (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-13 | Common Stock, $0.01 Par Value | A | 119000 | — | Acquired | 506509 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-13 | Performance Restricted Stock Unit | $ | A | 145000 | Acquired | Common Stock, $0.01 Par Value (145000) | Direct |
Footnotes
F1: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2: Includes 2,093 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024.
F3: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F4: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.